If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for comply with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of Securities Act. ☐ As filed with the Securities and Exchange Commission on October 16, 2025. UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 Amendment No. 13 to FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 FUNCTIONAL BRANDS INC. (form ...

Group 1: Company Performance - RF Acquisition Corp II Right (NASDAQ:RFAIR) experienced a significant stock price drop of 33.33% to $0.12, attributed to investor skepticism regarding future prospects and broader market trends affecting speculative investments [1][7] - Electra Battery Materials Corporation (NASDAQ:ELBM) saw a decline of 32.91%, with its stock price falling to $4.71, potentially influenced by disruptions from the Canada Post strike and fluctuations in the electric vehicle market [2][7] - Paranovus Entertainment Technology Ltd. (NASDAQ:PAVS) reported a decrease of 32.06% to $0.69, reflecting changes in company direction, Chinese regulatory policies, and shifts in consumer demand within the health and wellness sector [3][7] - Sunshine Biopharma, Inc. (NASDAQ:SBFMW) faced a decline of 31.67%, with its stock price dropping to $0.23, possibly influenced by updates on drug development and regulatory approvals [4] - OneMedNet Corporation (NASDAQ:ONMDW) saw a decrease of 25.09% to $0.15, facing challenges related to market adoption and competition in the AI healthcare space [5] Group 2: Market Trends and Influences - The stock movements highlight the volatility across various sectors, including technology, healthcare, renewable energy, and consumer goods, indicating diverse factors influencing company performance [6]

Core Insights - BioAdaptives, Inc. has launched MyndMed™, a cognitive-support dietary supplement aimed at enhancing memory, focus, mental clarity, and overall brain performance, with production scaling to meet anticipated demand in Q4 [1][2] Product Details - MyndMed™ combines well-studied nutrients to support cognitive pathways, including cholinergic tone, neuronal energy metabolism, antioxidant defenses, and neuroplasticity, promoting sustained alertness, calm focus, and memory support in the short term [2][5] - The product is compliant with World Anti-Doping Association (WADA) regulations, making it suitable for athletes seeking cognitive enhancement [2] Availability - MyndMed™ is currently available for purchase online at www.MyndMed.com, with shipping options across the U.S. and promotional offers for subscriptions [3] Company Background - BioAdaptives, Inc. focuses on developing science-based natural health and wellness products, leveraging research in stem cell biology, adaptogens, and regenerative nutrition to enhance quality of life [4] Quality Assurance - The product is manufactured in the USA in cGMP-certified facilities and undergoes third-party testing for identity, purity, and heavy metals, ensuring transparency in labeling without proprietary blends [6]

Core Insights - Cosmos Health Inc. has entered into an exclusive distribution agreement with Diyar United for its Sky Premium Life® nutraceuticals in Kuwait, marking a strategic expansion into the Middle Eastern market [1][2][6] - The agreement grants Diyar United exclusive rights for the registration, promotion, logistics, and distribution of various food supplements, including collagen, vitamins, and herbal blends [3][4] - The initial purchase order exceeds 65,000 units, indicating strong demand and a growing sales pipeline in Kuwait [4] Market Opportunity - Kuwait's nutritional supplements market was valued at approximately $1.16 billion in 2024 and is projected to reach $1.68 billion by 2030, growing at a CAGR of around 6.3%, presenting a significant opportunity for Cosmos Health [5] - The partnership with Diyar United, a respected distributor with extensive healthcare experience, is expected to enhance Cosmos Health's market penetration in Kuwait [2][6] Company Overview - Cosmos Health Inc. is a diversified, vertically integrated global healthcare group with a portfolio of proprietary pharmaceutical and nutraceutical brands, including Sky Premium Life® [7] - The company operates under European Good Manufacturing Practices (GMP) and is involved in the manufacturing and distribution of pharmaceuticals, food supplements, and medical devices across Europe, Asia, and North America [7] - Cosmos Health is also engaged in R&D partnerships targeting major health disorders and has entered the telehealth space through the acquisition of ZipDoctor, Inc. [7]

Core Insights - Cosmos Health Inc. is at a pivotal moment, having refined its strategy and operations to foster sustainable growth and long-term value creation [1][3] - The company aims to create a global healthcare platform integrating various sectors, including pharmaceuticals, nutraceuticals, and digital finance [4][5] - The ambition for 2030 is to transform into a global powerhouse by scaling branded products and leveraging AI and blockchain technologies [6][7] Vision & Ambition - The company has aligned all business units towards a common goal of making high-quality healthcare accessible globally [4][5] - Cosmos Health emphasizes resilience, creativity, and leadership in rapidly evolving industries [5] Milestones & Achievements - Significant progress has been made in financing, manufacturing capabilities, and innovation pipeline, including securing a $300 million financing facility [9][11] - The company has expanded its manufacturing footprint and strengthened its wholesale operations [10][18] Financial Performance & Outlook - In 2024, Cosmos Health reported revenues of approximately $54.43 million, a 2% increase from 2023, with a notable reduction in operating expenses [40][41] - The company aims for continued growth and profitability, targeting approximately $155.8 million in revenue by 2027 [48][44] Strategy & Roadmap - The growth strategy is built on six pillars, focusing on profitability, cash flow, and scaling high-margin businesses [46] - The company is committed to maintaining financial strength while pursuing innovation and global expansion [49][52] R&D and Innovation - Cosmos Health is advancing its proprietary obesity treatment, CCX0722, and expanding its R&D pipeline across multiple therapeutic areas [25][30] - The company utilizes its AI-enabled platform, Cloudscreen, to enhance drug discovery and accelerate innovation [26][50] Global Expansion - The flagship brand, Sky Premium Life, is expanding internationally, with over 150 premium products and strong demand across various regions [18][19] - The company has established a dual manufacturing hub in the U.S. and Europe to enhance supply chain resilience [18][22] Insider Commitment - The CEO has invested over $18 million of personal capital into the company, demonstrating a strong alignment of interests with shareholders [34][35] Sustainability Commitment - Cosmos Health is focused on balancing growth with social responsibility, emphasizing innovation, market development, and digital asset strategies [53][54]

Core Insights - The demand for health and preventive care products is significantly increasing in Asia and globally, presenting both opportunities and challenges for the industry [3] - Mom's Garden showcased its "0 laxative" gut health solutions at the Vitafoods Asia 2025, attracting attention from international clients and industry partners [1][3] Industry Overview - The Vitafoods Asia serves as a crucial international platform for Asia-Pacific enterprises to grasp trends and connect resources amidst rising international competition, high R&D costs, and regulatory compliance challenges [3] - The event highlighted the growing market for health products, with a focus on innovative solutions that cater to regional consumer needs [3] Company Highlights - Mom's Garden, established in 2002, emphasizes "scientific nutrition, natural power" and focuses on gut health and bone care, aiming to provide natural, safe, and long-lasting dietary solutions [8] - The brand has achieved significant success in the European and American markets and entered the Asia-Pacific market in 2020, adapting to local dietary habits and cultural preferences [8] - The company plans to deepen its localized product strategy in the Asia-Pacific market, leveraging scientific evidence to develop safe and effective nutritional products tailored to regional consumer characteristics [8] Product Innovations - Mom's Garden's key products, including Baicao Garden Qingqing Tablets and Baicao Garden AKK Probiotics, utilize a targeted release system to address constipation and gut microbiome imbalances [5][6] - The "0 laxative" approach is designed to meet the demand for gentle and long-lasting solutions, contrasting with traditional gut health products that rely on stimulants [5][6]

Core Viewpoint - Cosmos Health Inc. has officially launched its U.S. operations with the introduction of its proprietary Sky Premium Life food supplements brand, marking a significant milestone in its expansion strategy into the world's largest nutraceuticals market [1][7]. Company Overview - Cosmos Health Inc. is a diversified, vertically integrated global healthcare group, incorporated in 2009 in Nevada, with a portfolio of proprietary pharmaceutical and nutraceutical brands [8]. - The company operates through subsidiaries in Europe and North America, focusing on manufacturing pharmaceuticals, food supplements, cosmetics, and medical devices [8]. Product Launch and Sales - The Sky Premium Life NOOR Collagen product, formulated with premium marine collagen tripeptide, is now available in the U.S. and is designed to support skin and joint health [3][5]. - Early sales momentum for NOOR Collagen is encouraging, with projections indicating it could generate over $12 million in annualized revenue [5][7]. Market Potential - The U.S. nutraceuticals market was valued at $163.7 billion in 2024 and is expected to grow at a CAGR of 6.2% through 2030, driven by increasing health awareness and demand for natural wellness solutions [6]. - The company anticipates strong gross margins of approximately 75% from its U.S. operations, indicating significant cash flow generation potential [5]. Strategic Commitment - Cosmos Health emphasizes its commitment to regulatory excellence and product integrity by manufacturing all Sky Premium Life products in GMP-certified, FDA-registered U.S. facilities [2]. - The launch of NOOR Collagen is the first step in a series of planned product introductions aimed at meeting strong consumer demand in the U.S. market [8].

company," and "emerging growth company" in Rule 12b-2 of the Exchange Act. | Large accelerated filer | ☐ | Accelerated filer | ☐ | | --- | --- | --- | --- | | Non-accelerated filer | ☒ | Smaller reporting company | ☒ | | | | Emerging growth company | ☒ | If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for comply with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of Securities Act. ☐ As f ...

Core Insights - Healthy Extracts Inc. has been invited to present at the ArcStone-Kingswood Growth Summit on September 18, 2025, in Toronto, Ontario [1] - The summit features over 20 high-growth companies and aims to facilitate strategic networking and insight-sharing among institutional and retail investors [1] Company Overview - Healthy Extracts Inc. operates as a platform focused on acquiring, developing, manufacturing, and marketing science-based nutraceuticals and oral delivery systems [1] - The company's products are targeted towards brain, heart, and metabolic health [1] Industry Context - The ArcStone-Kingswood Growth Summit 2025 is designed to connect high-growth companies with investors, highlighting the importance of networking in the nutraceuticals sector [1]

Group 1 - ProText Mobility, Inc. has had the "caveat emptor" designation removed and is now current in its corporate filing information, achieving OTCID Basic Market status [1] - The company specializes in the research, testing, and development of highly bioavailable botanical products using proprietary live plant extraction technology for nutraceutical and pharmaceutical applications [2]